{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:53:00Z","timestamp":1767912780104,"version":"3.49.0"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            ASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. To evaluate the anti-HSV activity of ASP2151, susceptibility testing was performed on viruses isolated from patients participating in a placebo- and valacyclovir-controlled proof-of-concept phase II study for recurrent genital herpes. A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected. ASP2151 inhibited HSV-1 and HSV-2 replication with mean 50% effective concentrations (EC\n            <jats:sub>50<\/jats:sub>\n            s) of 0.043 and 0.069 \u03bcM, whereas ACV exhibited mean EC\n            <jats:sub>50<\/jats:sub>\n            s of 2.1 and 3.2 \u03bcM, respectively. Notably, the susceptibilities of HSV isolates to ASP2151 and ACV were not altered after dosing with the antiviral agents. Taken together, these results demonstrate that ASP2151 inhibits the replication of HSV clinical isolates more potently than ACV, and HSV resistant to this novel helicase-primase inhibitor as well as ACV may not easily emerge in short-term treatment for recurrent genital herpes patients.\n          <\/jats:p>","DOI":"10.1128\/aac.00133-12","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T05:01:18Z","timestamp":1335243678000},"page":"3587-3591","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["Susceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, a Novel Helicase-Primase Inhibitor"],"prefix":"10.1128","volume":"56","author":[{"given":"Kiyomitsu","family":"Katsumata","sequence":"first","affiliation":[{"name":"Department of Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[{"name":"University of Colorado Hospital and Departments of Pediatrics, Medicine and Pathology, University of Colorado, Denver, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chono","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Takakura","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kontani","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.1.114-128.2003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-11-199412010-00004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm182"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2003.08.018","article-title":"Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus","volume":"61","author":"Chibo D","year":"2004","unstructured":"ChiboD DruceJ SasadeuszJ BirchC. 2004. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res. 61:83\u201391.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq198"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.868"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1980010107"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/32.suppl_A.121"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706446"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200302000-00015"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1386-6532(00)00169-4","article-title":"Herpes simplex virus antiviral drug resistance\u2014current trends and future prospects","volume":"21","author":"Field HJ","year":"2001","unstructured":"FieldHJ. 2001. Herpes simplex virus antiviral drug resistance\u2014current trends and future prospects. J. Clin. Virol. 21:261\u2013269.","journal-title":"J. Clin. Virol."},{"key":"e_1_3_2_14_2","volume-title":"Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Huang M","year":"2011","unstructured":"HuangM . 2011. No emergence of resistance under treatment with the novel HSV inhibitor AIC316 in persons with genital herpes, abstr. V-2941b. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules16097210"},{"key":"e_1_3_2_16_2","first-page":"14A","article-title":"Epidemiology of genital herpes","volume":"22","author":"Kinghorn GR","year":"1994","unstructured":"KinghornGR. 1994. Epidemiology of genital herpes. J. Int. Med. Res. 22(Suppl. 1):14A\u201323A.","journal-title":"J. Int. Med. Res."},{"key":"e_1_3_2_17_2","first-page":"51","article-title":"The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing","volume":"9","author":"Lafferty WE","year":"2002","unstructured":"LaffertyWE. 2002. The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes 9:51\u201355.","journal-title":"Herpes"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162304"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(02)00263-9"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.1.71"},{"key":"e_1_3_2_21_2","first-page":"2479","volume-title":"Fields virology","author":"Pellet PE","year":"2007","unstructured":"PelletPE RoizmanB. 2007. The family Herpesviridae: a brief introduction, p 2479\u20132499. In KnipeDM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"5"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.3.913-917.2001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq135"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis019"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509213331205"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcv.2006.08.023","article-title":"Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues","volume":"38","author":"Weinberg A","year":"2007","unstructured":"WeinbergA LearyJJ SariskyRT LevinMJ. 2007. Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. J. Clin. Virol. 38:139\u2013145.","journal-title":"J. Clin. Virol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/514600"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04638-9"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00133-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00133-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:01:29Z","timestamp":1645452089000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00133-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1128\/AAC.00133-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00133-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"2012-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}